increased the cost of U.S.-based R&D for some American firms, and reduced it for others, with little net impact on the fraction of R&D spending that U.S. firms do abroad. One consequence of the tax law changes of the late 1980s is that, by 1991, the tax treatment of foreign-source royalties received by American firms with excess foreign tax credits has five times the tax-revenue impact of the Research and Experimentation Tax Credit.
INTRODUCTION
The U.S. government expends considerable effort, on a regular cycle, to consider and reconsider the tax treatment of research and development (R&D) . The Research and Experimentation (R&E) Tax Credit, introduced in 1981, is the most widely discussed tax-policy tool directed at R&D.
The original R&E credit was temporarydesigned to expire in 1985 but since 1985 the credit has been sequentially extended on a temporary basis. As a consequence, the R&E credit has been extensively discussed, and changed several times, over the period [1985] [1986] [1987] [1988] [1989] [1990] [1991] [1992] [1993] . The same is true of several other tax provisions that affect R&D. For example, President Clinton's budget proposal of February 1993 included numerous recommended changes in the tax treatment of R&D activities, with special attention devoted to R&D performed by multinational corporations. The Omnibus Budget Reconciliation Act of 1993, passed by Congress and signed by the president in August 1993, contains many of the features of the president's proposal of February 1993, but does not embody the sweeping reforms of the taxation of the R&D activities of multinational corporations recommended by the president.
Congress has struggled for years to design an approach to taxing R&D that is consistent with its tax revenue needs and its desire to encourage R&D. Concern over the responsiveness of R&D to tax rates is most acute in the case of multinational firms, since they have the ability, and often the incentive, to shift domestic operations to overseas locations in reaction to tax changes. Over the years, Congress has been particularly concerned that American firms might shift their R&D activities to offshore locations in response to tax changes that make it more expensive to undertake R&D in the United States. This concern is motivated in part by the belief that R&D in the United States generates valuable external benefits for the United States economy, and in part by a sense of urgency fueled by frequent reminders from corporate taxpayers I Griliches (1991) surveys recent empirical measures of productivity spillovers from R&D activities. Norton (1993, p. 38 ) quotes Intel's vice president for tax on the government's unwillingness to enact a permanent tax policy toward R&D: "The signal such constant uncertainty sendsa U.S. multinational is, do your R&D offshore."
A growing body of evidence suggests that the level of R&D activity in the U.S. may be quite sensitive to its tax treatment. This evidence comes from observing the reaction of U.S. R&D expenditures to the tax changes of the 1980s. In turn, the discussion of proposed tax reforms is, at times, informed by the evidence of the responsiveness of R&D to its after-tax cost. This paper examines the issues that arise in designing the U.S. tax treatment of R&D performed by multinational corporations, in the light of what now appears to be strong evidence concerning the responsiveness of R&D to its after-tax cost. Specifically, the paper considers the question of why U.S. multinationals did not expand their foreign R&D activities more rapidly after passage of the U.S. Tax Reform Act (TRA) of 1986. The TRA provisions reduce the tax deductions that many American firms can claim for their R&D expenses incurred in the United
States. For these firms, the TRA increases the relative attractiveness of doing R&D in foreign locations, and on this basis, many observers expected that U.S. firms would significantly increase the fraction of their R&D that they perform abroad.2 As it happens, the evidence indicates that this fraction changed very little after 1986.
The explanation for the difference between the expected and realized behavior after 1986 lies partly in the changing foreign tax credit status of firms that perform R&D in the United States for use in foreign markets. The 1986 TRA lowered the statutory U.S. corporate tax rate from 46 percent to 34 percent, thereby greatly increasing the number of U.S. corporations with excess foreign tax credits. American law has always afforded very favorable tax treatment to R&D performed in the United States for use abroad when the company undertaking R&D in the United States has excess foreign tax credits. Hence the firms that moved from deficit foreign tax-credit status to excess foreign tax-credit status as a result of the TRA faced new, and stronger, incentives to do R&D in the United States for use abroad. Firms with excess foreign tax credits both before and after passage of the TRA faced higher tax costs of doing R&D in the United States after passage of the TRA. Calculations indicate that the reactions of the two groups of firms should roughly balance each other out, with some firms moving additional R&D offshore and others intensifying their domestic R&D activities, the net result being that the aggregate fraction of R&D performed abroad by U.S. companies should be little affected by the 1986 tax act.
Section 2 of this paper reviews some recent trends in the level of R&D spending in the United States. The evidence indicates that American firms perform a significant fraction of their R&D abroad, but that the large offshore migration of R&D that some feared might materialize in reaction to changes in U.S. tax law in the late 1980s failed to take place.
Section 3 describes the tax changes introduced in the 1980s and the incentives they create for American firms that undertake R&D in the United States. Section 4 considers the evidence on the responsiveness of R&D to tax changes. Section 5 analyzes the reaction of R&D activity to the 1986 Tax Reform Act, and examines the impact of the generous tax treatment of R&D performed in the United States and used abroad.
Section 6 is the conclusion.
TRENDS IN R&D
The U.S. tax incentives for R&D introduced in 1981 reflect government concern over lagging U.S. R&D efforts in the 1970s. Table 1 describes the trends in the R&D/GNP ratios for the United States, France, Germany, Japan, and the United Kingdom over the period. The U.S.
R&DIGNP ratio declined from 2.9 percent in 1964 to 2.1 percent in 1978.
This ratio then climbed steadily in the 1980s, peaking at 2.8 percent in [1985] [1986] [1987] . Over the same time period, France and the United Kingdom had steady (and somewhat lower) R&DIGNP ratios, while Germany and Japan exhibited growing R&D intensity. It is not difficult to see in Table 1 the trends that motivated Congress to enact more generous tax treatment of R&D in 1981. Falling U.S. R&D intensity, at the same time that the German and Japanese economies were becoming more R&D intensive, drew the attention of those with concerns about maintaining U.S. technological leadership. Whether due to policy changes or to other factors, the end of the 1970s was a turning point for U.S. R&D.
The aggregate numbers displayed in Figure 1 mask two significant developments in R&D activity in the 1980s: variations in the amount of R&D performed by U.S. firms abroad, and the growing fraction of R&D in the United States performed by foreign-owned firms. The first of these two has been of particular concern to Congress in designing R&D tax policy. In spite of the difficulty firms have in finding cost-effective ways of doing R&D projects in certain foreign locations, Congress was concerned that the foreign share of the total R&D expenditures of American companies might rise along with the general trend to globalize American business.3
The U.S. Congress, Joint Committee on Taxation (1992, p. 49) reports that the "principal reason" behind changing the R&D allocation rules in 1981 was Congress's feeling that the There are several considerations that can complicate the interpretation of the data presented in Figure 1 . Tax changes roughly coincide with turning points in the fraction of U.S. R&D performed abroad, but so do other changes in the economic and scientific environment. One of the most obvious economic factors that might influence the ratio presented See Hines (1991a) for a discussion of the growing share of U.S. corporate profits attributable to the foreign operations of U.S. corporations.
The data on which Figures 1-3 are based come from a National Science Foundation (1993) survey of virtually all firms in the United States with annual R&D expenditures of $1 million or more. The survey is directed at R&D performed in the United States, and partly for that reason has a somewhat disappointing response rate to its question about R&D performed by foreign affiliates. There are other omissions as well; Cohen and Levin (1989) note that R&D reported in Compustat files is 12 percent greater than R&D reported in the NSF survey, and there is a view that the Compustat figures are the more reliable ones.
Nevertheless, the NSF surveys cover the foreign R&D undertaken by the largest firms, and appear to capture the important aggregate trends in R&D activity. in Figure 1 is the value of the U.S. dollar relative to foreign currencies. If real foreign and domestic expenditures on R&D do not change between two years, but the dollar weakens, then the dollar-denominated value of foreign R&D will rise relative to the value of domestic R&D. In order to examine the degree to which exchange-rate movements might influence the ratio presented in Figure 1 , Figure 2 plots an adjusted ratio in which the foreign R&D figure in the numerator is deflated by the tradeweighted value of the U.S. dollar (taking the 1977 value of the dollar against foreign currencies to be unity). The locus pictured in Figure 2 looks similar to that in Figure 1, 10.2 percent of the total. Figure 3 presents a variant of Figure 2 , in which the denominator is adjusted to include only the U.S.-owned component of R&D performed in the United States.6 The shape of Figure 3 is quite similar to the shape of Figure 2 , reflecting the rather modest (though growing) foreign-owned share of total U.S. R&D expenditures. It follows that the fraction of total U.S. R&D activity performed abroad is roughly constant over the 1977-1990 period, and its constancy is robust to an exchange-rate correction and adjustment for foreign R&D activity in the United States. law, followed by a description and analysis of the R&E credit. Then the section describes in general terms the U.S. tax treatment of foreign income earned by U.S. corporations, and analyzes its interaction with the tax treatment of R&D. The section ends by considering the impact of these rules on firms' incentives to undertake R&D.
THE TAX TREATMENT OF R&D

General Treatment of R&D
Expenditures on research and development by firms in the United States are deductible for income tax purposes.8 Since a firm's stock of R&D usually has the character of a capital good, in that it generates revenues both currently and over a number of future years, immediate expensing of R&D is an attractive tax feature.9 By contrast, physical capital such as plant and equipment is depreciated for tax purposes, and, despite occasional inducements such as the investment tax credit, has always been tax-disfavored relative to R&D.'° Generally speaking the effective rate of tax on R&D is zero, since firms will choose R&D expenditures that equate the (after-tax) marginal product of R&D to the (after-tax) cost of R&D. Since the same tax rate applies to both the marginal product of R&D and the marginal cost, the tax rate should not influence the level of R&D.
TheR&E Credit
The research and experimentation (R&E) credit was introduced in 1981 to stimulate additional R&D activity in the United States.1' The R&E credit initially offered a 25% tax credit for R&D expenditures above a base level, determined by the average of a firm's previous three years' Ravenscraft and Scherer (1982) find that the profitability of the firms in their sample appeared to be influenced by their R&D expenditures lagged four to six years. Griliches and Mairesse (1984) estimate firm productivity to be a function of the stock of accumulated R&D capital, which they take to depreciate at a rate of 15 percent per year; Jaffe (1986) also uses 15 percent as the exponential rate of depreciation for the R&D stock. In their study of patent renewals Pakes and Schankerman (1984) find evidence of a somewhat higher depreciation rate for R&D capital, 25 percent per year, but one that is much below the 100% rate that is implied in the tax law.
10 See Auerbach (1983) for a historical survey of the effective tax rates on investments in plant and equipment.
1
There are some small distinctions between activities that qualify for the R&E credit and R&D that is deductible but must be allocated according to 1.861-8. The Tax Reform Act of 1986 tightened the definition of R&D that is eligible for the tax credit.
worth of R&D expenditures. The idea behind the design of the credit was to offer an incentive for marginal research activities, but one that did not subsidize inframarginal research. Of course, in practice matters are not so simple, and the R&E credit could often have the perverse effect of discouraging research and development, or of providing only trivial incentives to undertake marginal R&D. The reason is that, by undertaking additional R&D activities today, a firm may reduce the credit it would otherwise receive in future years. Furthermore, various limits built into the credit reduce the incentive it provides in certain cases.12
The R&E credit came under fire from various arguments that implied that it was not a cost-effective way of stimulating R&D.13 Partly in response, the Tax Reform Act of 1986 reduced the R&E credit to 20 percent and tightened some of the definitions of R&D eligible for the credit. The 1988 tax act further reduced the subsidy afforded by the R&E credit by making half of the credit amount taxable income, and the 1989 tax act made the credit amount 100 percent taxable. In addition, the 1989 act changed the way that the base is calculated, with the intention that, starting in 1990, additional R&D expenditure in one year does not reduce a firm's tax credit in subsequent years.
The 1989 changes in the R&E credit illustrate some of the complications that accompany efforts to subsidize marginal R&D activities while not expending tax revenue to pay for inframarginal R&D. Taxpayers in each year are eligible for the R&E credit to the extent that their R&D expenditures exceed that year's firm-specific "base amount." The "base amount" is the product of the taxpayer's average gross receipts for the preceding four years and the taxpayer's "fixed base percentage." For firms with sales and R&D expenditures during at least three of the years 1984-1988, the "fixed base percentage" is the ratio of its R&D expendi-12 For example, R&D expenditures in excess of 200 percent of the base amount were eligible for only half the credit rate, even though they raise the base for future years. Furthermore, firms must have taxable profits (or the potential to carry credits forward or backward against taxable profits) to benefit from the credit. See Eisner, Albert, and Sullivan (1984) , Altshuler (1988), and Hall (1993) for analyses of the effective rates of subsidy provided by the R&E credit. Eisner, Albert, and Sullivan estimate the average effective credit rate for 1981 to be zero and for 1982 to be 4 percent. Altshuler, using a slightly different methodology, finds the effective credit rate for 1981 to be between 1 percent and 2 percent. Hall finds the effective credit rate to be 3 percent in 1981 and 5.1 percent in 1982; she reports that the credit rate subsequently jumped from 2 percent in 1989 to 7.7 percent in 1990 and 7.5 percent in 1991.
See, for example, Mansfield (1986) , who argues that the R&E credit had only a very small effect on R&D in the United States, and that it reduced tax collections by an amount equal to three times the additional R&D it generated. Wozny (1989) and the U.S. General Accounting Office (1989) report similar findings for a study of the R&E credit conducted by GAO. tures to its sales over that period. The idea behind this formula is to use data from the 1984-1988 period to construct firm-specific R&D targets, based on sales, that the firm might be expected to meet in the absence of a credit. Firms then receive R&E credits for their R&D expenditures in excess of the targets.'4 Serious problems can arise in defining these firm-specific targets, since firms need not remain identical over time: they are born, grow, die, merge, and do other things that change the character of the entity that existed during [1984] [1985] [1986] [1987] [1988] . The 1989 law provides that firms without sales and R&D in at least three years over the 1984-1988 period are assigned "fixed base percentages" of 0.03. Special rules apply to firms that merge. The difficulty that lies behind the design of these rules is that any adjustment of the "fixed-base percentage" that is itself a function of currentyear R&D efforts will often distort firms' incentives to undertake R&D in the current year, typically giving firms incentives to reduce their current R&D expenditures.
Disagreement over budgetary issues in general, and the appropriate treatment of R&D in particular, prevents Congress from designing a permanent approach to taxing R&D. The R&E credit was extended for one year by the Omnibus Budget Reconciliation Act of 1990, and for six months by the Tax Extension Act of 1991, until it expired on June 30, 1992. The R&E credit was reinstated (and made retroactive to June 30, 1992) by the August 1993 passage of the Omnibus Budget Reconciliation Act of 1993. Under the terms of the 1993 Act, the R&E credit is now due to expire on June 30, 1995. In addition, the 1993 Act provides a formula whereby the "fixed-base percentages" of start-up firms will slowly adjust from the statutory 3 percent to their average R&D/sales ratios over a period of years.
The scope of the corporate Alternative Minimum Tax (AMT) was greatly expanded by the Tax Reform Act of 86, including some provisions that bear on the tax cost of undertaking R&D. Firms paying the AMT are ineligible for the R&E credit, though AMT firms are permitted to carry their R&E credits forward (for up to 15 years) and can use them when out of AMT status. In addition, the foreign tax credit calculation under the AMT differs from the foreign tax credit calculation under the regular corporate tax, thereby influencing the after-tax cost of R&D for certain multinational firms.15
Some of the important R&D tax changes of the 1980s concern the taxation of U.S. firms with foreign income. In order to analyze these tax changes, it is necessary to consider some of the international features of the U.S. tax system.
U.S. Taxation of Foreign Income16
The United States taxes income on a "residence" basis, meaning that American corporations and individuals owe taxes to the U.S. government on all of their worldwide income, whether earned in the United States or not. The top U.S. corporate tax rate is now 35 percent. Since foreign profits are usually taxed in host countries, U.S. law provides a foreign tax credit for income taxes (and related taxes) paid to foreign governments, in order not to subject American multinationals to double taxation. The foreign tax credit mechanism provides that a U.S. corporation earning $100 in a foreign country with a 12 percent tax rate (and a foreign tax obligation of $12) pays only $23 to the U.S. government, since its U.S. corporate tax liability of $35 (35 percent of $100) is reduced to $23 by the foreign tax credit of $12. The foreign tax credit is, however, limited to U.S. tax liability on foreign income; if, in the example, the foreign tax rate were 50 percent, then the firm pays $50 to the foreign government but its U.S. foreign tax credit is limited to $35. Hence a U.S. firm receives full tax credits for its foreign taxes paid only when it is in a "deficit credit" position, that is, when its average foreign tax rate is less than its tax rate on domestic operations. A firm has "excess credits" if its available foreign tax credits exceed U.S. tax liability on its foreign income. Firms average together their taxable incomes and taxes paid in all of their foreign operations in calculating their foreign tax credits and the foreign tax credit limit.17
Deferral of U.S. taxation of certain foreign earnings is another important feature of the U.S. international tax system. A U.S. parent firm is taxed on its subsidiaries' foreign income only when returned ("repatri-16 Parts of this brief description of the tax system are excerpted from Hines (1991b) .
17 In order to qualify for the foreign tax credit, firms must own at least 10 percent of a foreign affiliate, and only those taxes that qualify as income taxes are creditable. Furthermore, income is broken into different functional "baskets" in the calculation of applicable credits and limits. Income earned and taxes paid in the conduct of most types of active foreign business operations are grouped in one "basket"; petroleum industry income is grouped in a separate "basket"; and there are separate "baskets" for items such as passive income earned abroad. The "basket" distinctions imply that a firm might simultaneously have excess foreign tax credits in the petroleum "basket" (which is common, since foreign tax rates on oil income are typically quite high) and deficit foreign tax credits in the active income "basket." Such a firm would have to pay some U.S. tax on its active foreign income, even though it has excess foreign tax credits on its petroleum income.
ated") to the parent corporation. This type of deferral is available only to foreign operations that are separately incorporated in foreign countries ("subsidiaries" of the parent) and not to consolidated ("branch") operations. The U.S. government taxes branch profits as they are earned, just as it would profits earned within the United States.
The deferral of U.S. taxation may create incentives for firms with lightly taxed foreign earnings to delay repatriating dividends from their foreign subsidiaries.'8 This incentive arises in those cases in which firms expect never to repatriate their foreign earnings, or if they anticipate that future years will be more attractive for repatriation (either because domestic tax rates will be lower, or because future sources of foreign income will generate excess foreign tax credits that can be used to offset U.S. tax liability on the dividends).'9 It appears that, in practice, U.S. multinationals choose their dividend repatriations selectively and generally pay dividends out of their more heavily taxed foreign earnings first.'° Consequently, the average tax rate that firms face on their foreign income need not exactly equal the average foreign tax rate faced by their branches and subsidiaries abroad.
Branch earnings and dividends from subsidiaries represent only two forms of foreign income for U.S. income tax purposes. Interest received from foreign sources also represents foreign income, though foreign interest receipts are often classified within their own "basket" and hence are not averaged with other income in calculating the foreign tax credit. Royalty income received from foreigners, including foreign affiliates of U.S. firms, is also foreign-source income. Foreign governments often impose moderate taxes on dividend, interest, and royalty payments from foreign affiliates to their American parent companies; these withholding taxes are fully creditable against a U.S. taxpayer's U.S. tax liability on foreign income.
18 The incentive to defer repatriation of lightly taxed subsidiary earnings is attenuated by the Subpart F provisions, introduced into U.S. law in 1962, that treat a subsidiary's passive income, and income invested in U.S. property, as if it were distributed to its American owners, thereby subjecting it to immediate U.S. taxation. The Subpart F rules apply to controlled foreign corporations, which are foreign corporations owned at least 50 percent by U.S. persons holding stakes of at least 10 percent each. Controlled foreign corporations that reinvest their foreign earnings in active businesses can continue to defer their U.S. tax liability on those earnings. See Hines and Rice (forthcoming) and Scholes and Wolfson (1991) for the behavioral implications of these rules.
Interaction of R&D and Foreign Income Rules
U.S. firms with foreign income are generally not permitted to deduct all of their R&D expenditures in the United States against their domestic taxable incomes. Instead, the law provides for various methods of allocating R&D expenses between domestic and foreign income. The intention of the law is to retain the relatively generous treatment of R&D, but only for that part of a firm's R&D expenditures that is devoted to production for domestic markets. R&D-performing firms with foreign sales and foreign income are presumed to be doing at least some of their R&D to enhance their foreign profitability.
From the standpoint of taxpaying firms, the U.S. tax law's distinction between domestic and foreign R&D deductions is potentially quite important. If an R&D expense is deemed to be domestic, then it is deductible against the taxpayer's U.S. taxable income. Alternatively, if it is deemed to be foreign, then the R&D expense reduces foreign taxable income for the purposes of U.S. income taxation only. Foreign governments do not use U.S. methods of calculating R&D deductions, and generally do not permit U.S. firms to reduce their taxable incomes in foreign countries on the basis of R&D undertaken in the United States. Consequently, an R&D expense deduction allocated against foreign income is valuable to a U.S. firm only if the firm has deficit foreign tax credits. If the firm has deficit credits, then the firm pays some U.S. tax on its foreign income, and any additional dollar of R&D deduction allocated against foreign income reduces the firm's U.S. taxable income by a dollar.21 Hence, firms with deficit foreign tax credits are indifferent between allocating R&D expenses against foreign income and allocating them against domestic income. By contrast, firms with excess foreign tax credits pay no U.S. tax on their foreign income, and therefore have no use for R&D deductions allocated against foreign income. Consequently, firms with excess foreign tax credits lose the value of any R&D deductions allocated against foreign income.
The tax law governing the allocation of R&D expenses was for years rather vague, but was codified by U.S. Treasury Regulation 1.861-8 in 21 Curiously, the law is written so that the additional dollar of R&D deduction reduces taxable income without reducing the foreign tax credits available for foreign income taxes paid.
This statement, along with much of the analysis described in the paper, abstracts from the ability of firms to carry excess foreign tax credits backward two years and forward five years. Firms that can exploit carryforwards or carrybacks may (depending on specific circumstances) face incentives that are intermediate between those of deficit credit and excess credit firms.
1977. The 1977 rules provide for several stages in allocating R&D expenditures for tax purposes. R&D in the United States that is undertaken to meet certain legal requirements (such as R&D devoted to meeting pollution standards) can be 100 percent allocated against domestic income. Firms that perform more than half of their (other than legally required) R&D in the United States are permitted to allocate 30 percent of that R&D against U.S. income. The remaining 70 percent is then to be allocated between domestic and foreign sources on the basis of sales (including the sales of controlled foreign corporations). R&D is generally allocated according to activities within product lines (defined similarly to two-digit SIC codes), so that a corporation need not allocate part of its chemical R&D against foreign income simply because the electronics part of its business has foreign sales.
There are several options available to taxpayers who are unsatisfied with the outcome of the R&D allocation method just described. Firms are permitted to apportion more than 30 percent of their domestic R&D against U.S. income if they can establish that it is reasonable to expect the R&D so apportioned to have very limited application outside of the country; the remaining portion of its R&D expenses are then allocated on the basis of sales. Alternatively, firms are permitted to allocate their R&D on the basis of total foreign and domestic income (though without the 30 percent initial allocation to U.S. source), so that firms with foreign operations that generate sales but not income (relative to domestic operations) might prefer the income-allocation method. There is, however, a limit to the income-allocation method: firms are not permitted to reduce their R&D allocation to foreign source to less than 50 percent of the allocation that would have been produced by the sales method (including the 30 percent initial apportionment).
The Economic Recovery Tax Act in 1981 changed these rules by permitting U.S. firms to allocate 100 percent of their R&D performed in the United States against U.S. income. This change was intended to be temporary (two years), in order to offer strong R&D incentives, while affording Congress the opportunity to rethink its R&D policy. At the end of that time the U.S. Department of the Treasury produced a study (1983) concluding that the tax change offered a small R&D incentive to U.S. firms, and was desirable on that basis. 23 In 1984 and 1985 Congress 23 The Treasury study based its conclusions on a range of assumed elasticities of R&D with respect to price changes; there was no attempt made to ascertain how firms responded to the changes introduced in 1981. The Treasury study is a very careful analysis of firm-level, tax-return data and the significant issues involved in the §1.861-8 change. On the other hand, the Treasury study uses the average price reduction introduced by the 1981 tax-law change, rather than the changes in marginal prices of R&D and other inputs, to estimate the effects of the law. extended the temporary change permitting 100 percent deductibility of U.S. R&D expenses against U.S. income, so these rules remained in place until the end of the 1986 tax year.
The Tax Reform Act of 1986 removed the 100 percent deductibility of U.S. R&D expenses, replacing it with a new, and again temporary, system of R&D expense allocation.24 Under the 1986 Act, 50 percent of U.S. R&D expense (other than R&D to meet regulations, which was 100 percent allocated to domestic source) was allocated to domestic source, with the remaining 50 percent allocated on the basis of sales or income, at the taxpayer's choice. There was no limit imposed on the degree to which allocation on the basis of gross income could reduce foreign allocation relative to the sales method. These rules, it turned out, were in The Omnibus Budget Reconciliation Act of 1989 again changed the R&D allocation rules, this time reintroducing the same rules that applied for the first four months of 1988. The Omnibus Budget Reconciliation Act of 1990 and the Tax Extension Act of 1991 extended this treatment of R&D expenses until a date that depends on a taxpayer's choice of fiscal year, but in no case later than August 1, 1992. Consequently, 64 percent of domestically performed R&D in 1989-1992 could be allocated against domestic income, with the remaining 36 percent allocated either on the basis of sales or of income (though use of the income method could not reduce foreign-source allocation to less than 30 percent of the foreignsource allocation that would have been produced by the sales method).
The expiration of the R&D expense-allocation legislation in the sum- moratorium in which taxpayers could continue to use the system embodied in the legislation covering the years 1989-1992 (64 percent place-ofperformance allocation, with the remaining deductions allocated on the basis of sales). The idea was that the Treasury would reexamine its §1.861-8 regulations during the eighteen-month period. The rationale for the moratorium was "to provide taxpayers with transition relief and to minimize audit controversy and facilitate business planning during the conduct of the regulatory review."25 Some contemporaneous observers noted that the extension of the R&D allocation rules through Treasury moratorium instead of Congressional legislation made the rules less costly from the standpoint of federal budget targets, since regulatory changes are exempt from the budget-agreement limits. What role, if any, such considerations played in the decision to suspend the §1.861-8 rules is not clear. In any case, the Treasury moratorium did not run its full course, being supplanted in 1993 by new legislation. President Clinton's budget proposal of February 1993 recommended a major change in the allocation of R&D expenditures and treatment of royalty receipts by U.S. -based multinational corporations. The president proposed that U.S. firms deduct 100 percent of their U.S. R&D expenditures against U.S. income, but that the same firms no longer be permitted to use foreign tax credits generated by their active foreign operations to reduce U.S. tax liabilities on royalty income from foreign sources. Instead, firms would be required to allocate foreign-source royalty income to the "passive basket" in determining their foreign tax-credit limits. The idea behind the change was to limit severely the ability of U.S. firms to use excess foreign tax credits to wipe out their U.S. tax liabilities on foreign-source royalty income. Very few firms have excess foreign tax credits in the "passive basket." Consequently, the overall effect of the proposal would have been to raise the deductions that firms with excess foreign tax credits receive for R&D performed in the U.S., but to includeas income fully taxed by the United Statesthe royalties they receive from foreign sources. Congress chose not to include this proposal in the legislation passed in August 1993.
Instead, the Omnibus Budget Reconciliation Act of 1993 (OBRA 93) continues the pattern of allowing U.S.-based multinational firms to deduct only a fraction of their U.S. R&D expenses against U.S. income, and, at the same time, permits firms to use excess foreign tax credits to eliminate U.S. tax liabilities on foreign-source royalty income. OBRA 93 permits firms to allocate 50 percent of U.S-based R&D expenses to domestic source, with the remaining 50 percent allocated between domestic and foreign source, based either on sales or on income, at the taxpayer's option (subject to the restriction that income-based allocation not reduce foreign-source allocation to less than 30 percent of that produced by the sales method). The allocation rules under OBRA 93 are temporary, expiring one year after they take effect. As in earlier years, many observers attribute the temporary nature of the allocation rules to the mechanics of compliance with federal budget targets: if Congress were to pass permanent legislation covering the R&D allocation rules, then the "cost," to the current-year budget, of any treatment more generous than the 1977 regulations must include costs incurred in future years. By instead passing temporary legislation, Congress incurs budgetary costs only for the current year. Of course, budgetary costs need not bear any relation to the economic consequences of permanent legislation covering the allocation of R&D expenses.26
The U.S. R&D expense allocation rules are intricate, subtle, and subject to frequent changes. For the purposes of analyzing the effects of legislative changes, however, a clear pattern emerges. All U.S. firms could deduct their R&D expenses against domestic income from 1981-1986. Starting in 1987, multinational firms with excess foreign tax credits are able to use only some of their R&D deductions, since part of their R&D deduction is allocated against foreign income (and thereby does not reduce their overall tax liabilities). For firms with deficit foreign tax credits, however, the period since 1987 is just as attractive as was 1981-1986, because even though some of their R&D expenses are allocated against foreign income, this foreign allocation reduces their U.S. tax liabilities by just as much as would an allocation against domestic income.
Incentives Created by the Tax Treatment of R&D
The tax treatment of R&D encourages firms to undertake R&D in the United States, at least relative to a system in which R&D is capitalized and depreciated according to the lifetimes researchers usually find commensurate with the time periods during which it enhances firm productivity. In addition to encouraging firms to undertake R&D, the law introduces 26 There are some with strong feelings that permanent legislation would create a more predictable environment for businesses and make the United States a more attractive location for R&D. Turro (1993, p. 436) quotes one tax practitioner, who describes Congress's decision to make the OBRA 93 R&D allocation rules temporary, an "absurd tax policy decision." somelargely unintendedincentives to alter the behavior of firms with significant R&D expenditures.
Many of the incentives introduced by the old (pre-1989) R&E credit have been analyzed extensively elsewhere.27 Because only some firms were eligible for the credit, and among the eligible firms many reduced their future credits by performing R&D in the current year, the R&E credit was not thought to have a significant impact on R&D spending levels. The R&E credit changes introduced in 1989 appear to offer firms stronger marginal incentives to undertake R&D, but (on average) had only a modest effect on the after-tax cost of R&D.
The impact of the tax treatment of R&D-performing multinational firms has received comparatively less attention. Here the issue is complicated in part by the nature of the lines of business for which the R&D is undertaken.
The simplest case is one in which a U.S. multinational firm performs R&D in the United States with the intention of using the research results in a U.S. market. Ignoring the R&E credit for the moment, the firm obtains full deductions for its R&D expenditure only when it has deficit foreign tax credits. If the firm has excess foreign tax credits, then the allocation of a fraction of its R&D deductions against foreign-source income makes this allocated fraction effectively valueless. Consequently, the R&D allocation rules affect differently the incentives of two otherwise-identical firms that perform R&D in the United States for use in the United States, making the effective cost of R&D higher for a firm with excess foreign tax credits than for a firm with deficit foreign tax credits. The difference arises because the law treats all U.S.-based R&D expenses as though they enhance worldwide sales, unless the taxpayer can demonstrate otherwise. There is a second, and more subtle, effect of the R&D allocation rules, in which firms with excess foreign tax credits and large R&D expenditures (as fractions of their overall businesses) are encouraged by the tax system to increase their ordinary business activities in the United States and reduce their foreign business activities. The reason is that greater U.S. sales permit more of their U.S.-based R&D deductions to be allocated against U.S. taxable income, whereas greater foreign sales have the opposite effect. This consideration then influences R&D expenditure decisions, since R&D spending generates additional sales. U.S.-based R&D that enhances U.S. sales permits firms to increase the allocation of their inframarginal R&D deductions against U.S. income, thereby amelio-rating some of the disincentive effects of the allocation rules for domestic R&D by those firms that are particularly R&D intensive.
If, instead, a firm undertakes R&D in the United States, intending to use it to enhance the sales of one of its foreign affiliates, then the tax system's incentives depend very much on whether the firm has excess foreign tax credits or deficit foreign tax credits. Foreign affiliates are required to pay royalties to their U.S. parent firms based on the market value of any technology they use to enhance their sales offshore. A firm with deficit foreign tax credits takes full advantage of its R&D deductions, but the royalties it receives from using its technology abroad are subject to overall taxation of the U.S. tax rate. A firm with excess foreign tax credits cannot make effective use of all of its R&D deductions, but the royalties that the firm receives are effectively exempt from U.S. tax, since the excess foreign tax credits can be applied against the U.S. tax liability generated by the royalties. As a consequence, firms with excess foreign tax credits face a very attractive tax environment when undertaking R&D in the U.S. for use abroad: the R&D expense is partially deductible, and the royalty income is exempt from tax.28
This analysis presumes that foreign affiliates pay royalties to the United States for the use of technology developed in the United States, as American and most foreign laws require. It is not always in the interest of a firm to pay royalties equal to the market value of the technology transferred from a related party. For example, the attractiveness of foreign royalty income to U.S. firms with excess foreign tax credits gives some firms incentives to maximize the payment of royalties from their own affiliates in high-tax foreign locations, in order to obtain tax deductions against taxable income in foreign countries. Kopits (1976) offers evidence that is consistent with behavior of this type. Tax authorities are aware of this problem, but it can be very difficult to establish market prices for technologies transferred to related foreign affiliates. In such an environment, firms often have the ability to report royalty charges that (within reasonable ranges) reduce their tax liabilities. There is, however, a limit to the degree to which royalty payments can deviate from reasonable amounts without generating activity from tax-enforcement agencies.
28 Two additional considerations influence the attractiveness of R&D undertaken in the United States for use abroad. The first is that certain foreign governments impose withholding taxes on royalty payments to U.S. corporations; these withholding taxes are costly to American firms with excess foreign tax credits, since those firms are over the foreign tax credit limit and cannot use the additional foreign tax payments to reduce their U.S. tax liabilities. Foreign withholding tax rates on royalties are typically quite low, however, on the order of 5 percent. The second consideration is that R&D that generates foreign sales affects the allocation of inframarginal R&D deductions between domestic and foreign income, raising the cost of that type of R&D when undertaken by firms for whom R&D deductions are large relative to sales. Some firms have incentives to adjust royalty payments for tax purposes, and some royalties are paid for the use of business know-how that may not be the product of R&D; nevertheless, in practice, R&D performance is highly correlated with royalty receipts. Data on the behavior of the foreign affiliates of U.S. corporations in 1989, as reported by the Bureau of Economic Analysis of the U.S. Department of Commerce (1992), indicate a close association between R&D activity and royalty receipts. Table 2 reports estimated coefficients from regressions in which the dependent variable is the ratio of royalties received by U.S.
affiliates in foreign countries to local sales of U.S. affiliates, each observation representing aggregate U.S. activity in one of the fifty countries for which data are available. The estimated coefficients imply that R&D! sales has a significant effect on royalty receipts/sales, even controlling for local GDP/sales.29 R&D/sales influences both total royalty receipts (reported in columns 1 and 2), and royalties received from unrelated 29 The results reported in Table 2 were very similar when rerun without the GDP/sales variable on the right side. parties only (reported in columns 3 and 4), the latter being arguably less subject to manipulation for tax purposes. BEA suppresses some of the royalty reports for confidentiality reasons; the results of regressions in which the suppressed observations are dropped (columns 1 and 3) are quite similar to those in which the suppressed observations are included as zero royalties (columns 2 and 4). Table 3 reports means and standard deviations for the variables used in the regressions. U.S. firms that perform R&D abroad are subject to the tax rules of their host foreign countries. Foreign-country tax rules differ, but most industrialized countries permit something like immediate deduction of R&D expenses, and a few have credit schemes that are similar to the U.S. R&E credit. American tax rules can also influence the cost of undertaking R&D abroad for use abroad, though the effect is subtle, since it comes primarily through its effect on the calculation of applicable foreign tax credits on dividends received from affiliates that do R&D.3° If U.S. firms perform their offshore R&D through foreign branches, or have explicit°° See Hines (1988) for an analysis of the importance of the U.S. rules that determine foreign income used in the calculation of applicable foreign tax credits. The figures analyze the incentives facing firms whose U.S. R&D is 5 percent of total sales, and for whom 35 percent of total sales arise in foreign markets. The foreign withholding tax rate on royalty income is assumed to be 5 percent, the pre-1986 U.S. corporate tax rate to be 46 percent, and the post-1986 U.S. tax rate to be 34 percent, and U.S. tax law is assumed to provide a 64 percent place-of-performance allocation of R&D deductions. Firms are assumed to be ineligible for the U.S. R&E credit, and ineligible for R&D-related credits provided by foreign governments; foreign governments are, however, assumed to permit immediate deduction of all R&D expenses. For the purposes of these calculations, the foreign tax-credit status of a U.S. multinational is assumed to be permanent, and the firm repat-riates its foreign earnings immediately.
cost-sharing arrangements with their foreign subsidiaries (for the fraclion of their R&D expected to generate U.S.-source income), then they are able to allocate a fraction of their foreign R&D costs against U.S. taxable income, subject to rules that are analogous to those that allocate U.S.-based R&D expenses. Table 4 offers illustrative calculations of the tax incentives embodied in pre-1986 and post-1986 U.S. law. For the purposes of these calculations, the pre-1986 U.S. tax rate is taken to be 46 percent and the post-1986 U.S. tax rate is 34 percent; the firm is assumed to have an R&D/sales ratio of 5 percent; 35 percent of the firm's sales are assumed to be foreign; the foreign withholding tax rate on royalties is assumed to be 5 percent; and U.S. law is assumed to provide a 64 percent place-of-performance allocation of R&D expenses, followed by sales allocation of the remaining 36 percent.31 Firms are assumed to be ineligible for the U.S. R&E credit, and ineligible for R&D-related credits provided by foreign governments; foreign governments are, however, assumed to permit immediate deduction of all R&D expenses. Foreign R&D is assumed to be conducted by ' Hines (1993) reports that a sample of 116 R&D-performing U.S. multinationals had an average of 35.4 percent foreign sales in 1989. The same study calculates the weightedaverage foreign withholding tax rate on royalties received in the United States (using 1984 weights) to be 4.9 percent. See also Table 8 , in which the average foreign withholding tax rate on royalties received by U.S. manufacturing firms in 1986 is 5.7 percent. Pre-1986 Post-1986 Pre-1986 Post-1986 R&D in the U.S. for use within the U.S. Table 4 indicates that the after-tax cost of R&D rose for firms with excess foreign tax credits after 1986. The required marginal productivity of $1 of R&D performed in the United States for use in the United States rose from $1 to $1.06, while the required marginal productivity of $1 of R&D performed in the United States for use abroad rose from $0.57 to $0.74. It is this second change that prompted concern over the possibility that R&D directed at foreign markets might move offshore. The change from $0.57 to $0.74 represents the outcome of two aspects of the tax law that changed in 1986: after 1986, firms were required to allocate some of their R&D deductions against foreign income, and in addition, the value of R&D tax deductions fell (relative to the effectively untaxed foreignsource royalty income of U.S. firms with excess foreign tax credits) as the U.S. corporate tax rate fell from 46 percent to 34 percent. Together, these features of the Tax Reform Act of 1986 noticeably reduced the attractiveness of R&D performed in the United States for use abroad by firms with excess foreign tax credits.
EVIDENCE ON THE EFFECTIVENESS OF TAX POLICY IN INFLUENCING R&D
There is a widely held view that R&D tax incentives are important to maintaining the U.S. competitive position in world markets. Implicit in this argument is the premise that the level of R&D activity responds significantly to tax incentives. Until recently, the academic literature did not provide strong support for the proposition that the real after-tax price of R&D significantly influences the level of business R&D activity.33 The reason may have to do with the difficulty of finding exogenous price changes. Earlier researchers typically use time-series variation in the real 32 See Hines (1993) for a derivation of these required productivities of marginal R&D expenditures.
See, for example, Bernstein and Nadiri (1989) , who estimate R&D price elasticities to lie between 0.4 and 0.5 for a sample of manufacturing firms, while Nadiri and Prucha (1989) find the R&D price elasticity to be much closer to zero for the U.S. Bell System. In a study of Canadian firms Bernstein (1985) reports estimated R&D price elasticities of between 0.1 and 0.4. Mansfield (1986 ), Hall (1993 , and the GAO study (1989) summarize the earlier literature with the conclusion that the consensus range of price elasticities is 0.2 to 0.5. The price elasticity one expects may be a matter of judgment, but many observers find the 0.2 to 0.5 range to be unreasonably close to zero. Certainly firms claim to be influenced by after-tax prices; Brown (1984) reports that, in a Conference Board survey conducted in 1984, two-thirds of the executives surveyed anticipated that tax incentives would influence their R&D expenditures over the next one to three years.
cost of R&D, making it impossible to exploit firm-specific variations, and raising a number of problems related to omitted variables and the endogeneity of the cost of R&D. Three recent studies challenge the conventional wisdom that the elasticity of demand for R&D is small. Baily and Lawrence (1992) estimate time-series regressions of R&D expenditures, using industry-level data to examine the after-tax price variation introduced over time by the introduction of the R&E credit and changes in the R&D cost-allocation rules. They find that tax policy significantly influences R&D spending, as a quick perusal of Table 1 might suggest: the R&D intensity of the U.S.
economy began rising at around the same time the R&E credit and full domestic deductibility expenditures were introduced. Baily and Lawrence report that the elasticity of R&D spending with respect to its aftertax cost is approximately one. The difficulty that this study encounters is that the regressions pick up the effects of tax changes and all other timespecific factors that influence R&D, attributing all of the effects to the tax changes. The advantage of the study is that it examines the aggregate effects of the credit.
Hall (1993) also finds a close to unit elastic responsiveness of R&D to the after-tax price of undertaking R&D, and does so using a methodology that differs significantly from that of Baily and Lawrence. She uses annual firm-level data on more than 700 of the largest U.S. firms, covering the period 1980-1991, to see if firms in the most tax-advantaged positions perform more R&D (as reported by Compustat) than do other firms. The great advantage of her procedure is that annual events, such as the dramatic technological developments that characterized R&D-intensive fields in the 1980s, are subsumed for all firms in year-specific effects. Consequently, she examines only the firm-specific considerations that affect the real cost of R&D. The difficulty that this procedure encounters is that it is not always clear exactly why some firms find themselves in tax-advantaged positions and others do not. The statistical procedure she uses conditions the current variables that determine firms' tax positions on their own lagged values, so she is able to check whether, for example, a firm with low R&D expenditures in the past, and consequently a low "fixed-base percentage," responds more sharply to the 1989 tax law change than do other firms with average past R&D expenditures. The evidence indicates that they do. Hines (1993) uses an alternative source of price variation to examine the effect of after-tax prices on the volume of R&D undertaken by U.S. multinational corporations. This study compares the post-1986 growth of R&D expenditures by two groups of U.S.-based multinationals: the first, a group with excess foreign tax credits, and the second, a group with deficit foreign tax credits. The change in the R&D cost-allocation rules introduced by the Tax Reform Act of 1986 raises the post-1986 aftertax cost of R&D for firms with excess foreign tax credits and significant foreign income and sales. The data indicate that this group of firms exhibited slower growth of post-1986 R&D spending than did the deficit credit firms for whom the R&D allocation rule change should have had little effect. Table 5 presents estimates of the responsiveness of R&D spending to Hines (1993) . Note: Values in parentheses are standard errors. PR and P1 are the two domestic tax prices relevant to R&D; PR and PI are their foreign counterparts (and are premultiplied by [S/S1). PR reflects the effect of the allocation of R&D tax deductions on the required marginal product of R&D. P1 is the effect of R&D tax rules on demand for R&D that arises from the desire on the part of (some) firms to expand their domestic output and thereby allocate greater R&D deductions against domestic income. PR reflects the effect of the R&D deduction allocation and the treatment of foreign-source royalties on the desired level of V.5.-based R&D spending designed to enhance sales in foreign markets. PP reflects the part of the effect of tax rules on U.S.-based R&D designed to enhance sales in foreign markets that arises from the desire on the part of (some) firms to reduce their foreign output. its changing after-tax cost in the 1980s, as reported by Hines (1993) . The coefficients in the first row of the table represent own-price [ln(PR)} demand elasticities; the estimates indicate that the own-price elasticity lies between 1.2 and 1.8, depending on specification.34 This represents a considerable responsiveness of R&D spending to the tax changes of the 1980s. The firms used in the sample represent the forty Compustat firms for which sufficient tax and R&D information was available, and was restricted to those with no significant merger activity over the [1984] [1985] [1986] [1987] [1988] [1989] period. When the same regressions were rerun on an expanded sample including seventy-six additional firms with significant but not major merger activity, the estimated elasticities are half the size of the estimates obtained from the smaller sample. Of course, the advantage of using a small sample of nonmerging firms is that the R&D activities of these firms are not directly affected by merger-driven changes in firm sizes; the disadvantage is that smaller sample sizes are usually associated with less precise estimates.
WHY DID AMERICAN FIRMS PERFORM SO LITTLE R&D ABROAD AFTER 1986?
The responsiveness of R&D to its after-tax price raises the question of why American firms, whose R&E credit is now less generous than it was earlier in the 1980s, and many of whom are no longer able to obtain full tax deductions for their R&D expenses, do not choose to locate a greater fraction of their R&D activities in foreign countries. This section analyzes this question.
R&D Performed Abroad for Use in the United States
There are two possible uses to which R&D performed abroad might be put. The first is to enhance sales abroad. The second is to provide valuable inputs to a firm's U.S. operations, and, by so doing, to enhance sales in the United States. The two uses are not necessarily separatea particular R&D project might serve both purposesbut the tax treatment of the two uses differs significantly.
Coefficients in the second line of Table 5 report the estimated elasticity of domestic R&D that enhances domestic sales with respect to the associated cost [ln(PI)] of changing the allocation of deductions for inframarginal R&D. Coefficients in the third line of Table 5 report the estimated elasticity of domestic R&D that enhances foreign sales with respect to its tax cost [ln(PR*)], and coefficients in the fourth line report the estimated elasticity of domestic R&D that enhances foreign sales with respect to the associated cost [ln(PI*)l of changing the allocation of deductions for inframarginal R&D. In addition, the regressions include firm-specific effects, year dummies, and foreign-sales fractions as explanatory variables. The point estimates of all of the cost terms in Table 5 have the predicted signs.
Firms with excess foreign tax credits faced higher costs after 1986 of doing R&D in the United States to promote sales in U.S. markets. The effects of these higher costs were somewhat ameliorated for firms that could benefit from the changes in the R&E credit after 1989, but there remains the possibility that some firms might move their R&D directed at U.S. markets to foreign locations.
There appears to be extremely little behavior of this type. American multinational firms virtually never use foreign locations to perform R&D for the American market. Table 6 reports various data items relevant to R&D performed for foreign markets, including the figures that, in 1982, U.S. multinationals paid only $36 million in royalties to their foreign affiliates; in 1989 these royalty payments were $54 million. These figures represent very small sums, even when compared with expenditures on R&D performed abroad by the same affiliates. It is possible that some of the R&D performed abroad is intended to etihance sales in U.S. markets, and, either because the R&D has not yet been fruitful, or for other reasons, royalties have not yet been paid, but the extremely small value of annual royalties indicates that the "headquarters effect" discussed by Hufbauer (1992) that firms undertake their major R&D efforts in proximity to their headquartersis quite strong, at least insofar as it pertains to R&D directed at the U.S. market.
There is a powerful tax reason why U.S. firms do very little R&D abroad when intending to exploit the R&D in the U.S. market. Firms performing R&D abroad and using the technology it generates in the United States are required to pay a royalty from the United States to the foreign affiliate. The royalty is taxable income in the foreign country. The royalty payment also generates a tax deduction for the U.S. firm making the payment, but at the same time is treated as U.S. "Subpart F" income (since special provisions apply to related-party royalty income) and is, therefore, taxed immediately in the United States. Under American tax law, the source of the royalty income is the location in which the technologyis used; in this case, the royalty income is U.S.-source income. Since the royalty income has U.S. source, foreign tax credits cannot be used to reduce the U.S. tax liability generated by the royalty. The overall result of R&D performed by a foreign affiliate for use by a parent firm in the United States is that the parent firm's tax deduction for its royalty payment is offset by the U.S.-source income generated by the royalty. At the same time, the foreign affiliate pays foreign taxes on the royalty it receives. This transaction is extremely expensive from a tax standpoint, so it is not surprising that it seldom occurs.
Effects of the Tax Reform Act of 1986
The 1986 tax changes might also prompt U.S. multinationals to move their R&D directed at foreign markets to closer proximity to foreign markets. Since U.S. firms tend to perform their offshore R&D in the same locations where they sell their goods, one outcome of the 1986 tax change could be to intensify this process. The regressions reported in Table 7 as reported by the National Science Foundation (1991); the estimates again imply that local sales, now interacted with R&D intensity, strongly influence R&D activity. The Bureau of Economic Analysis (BEA) suppresses some of the R&D data for confidentiality reasons; the results of regressions in which the suppressed observations are dropped (columns 1 and 2) are quite similar to those in which the suppressed observations are included as zero R&D (columns 3 and 4).35 Table 3 reports means and standard deviations for the variables used in the regressions. The regressions ignore the endogeneity of local sales to local R&D activity, and therefore In spite of the usefulness of R&D in locations where firms have significant sales, U.S. multinationals did not move their R&D offshore to a significant degree after 1986. Table 4 indicates one reason why they did not do so. Although it is true that, for firms continually in excess-credit status, the cost of U.S.-based R&D directed at foreign markets rose after 1986, it is also true that, for firms with deficit foreign tax credits prior to 1986 and excess foreign tax credits after 1986, the after-tax cost of R&D performed in the United States and directed at foreign markets fell significantly. For firms with deficit foreign tax credits prior to 1986 and excess foreign tax credits after 1986, the required marginal productivity of $1 of R&D directed at foreign markets fell from $1 before 1986 to $0.74 after 1986. One of the major effects of the reduction in the U.S. statutory tax rate from 46 percent in 1986 to 34 percent by 1988 was greatly to increase the number of firms with excess foreign tax credits. These firms should be viewed only as suggestive. The results reported in Table 7 are consistent with those reported by Mansfield, Teece, and Romeo (1979) would have stronger incentives to keep their foreign-directed R&D in the United States in 1988 than they did in 1986. Unfortunately, it is not possible to assess directly the magnitude of the R&D expenditures of firms that moved from deficit foreign tax-credit status to excess foreign tax-credit status after the tax-rate reduction in 1986, since such data are not available. It is, however, possible to use indirect evidence to estimate the importance of the R&D spending of firms that were in this situation. In a U.S. Department of the Treasury study, Goodspeed and Frisch (1989) estimate that U.S. parent firms with excess foreign tax credits received 50 percent of the foreign-source income of U.S. manufacturing firms in 1984, and projected that the 1986 tax changes would increase this figure to 78 percent.
Foreign-source income includes many items other than royalties, but it is reasonable to assume that firms with foreign-source royalty income from U.S. R&D activities are typical of all U.S. firms receiving foreignsource income. Table 8 offers some evidence on this point from U.S. corporate tax returns for 1986. The table presents an industrial breakdown of total foreign-source income, foreign-source rents, royalties, and license fees, and foreign tax credits claimed in 1986. The average foreign tax rate for all industries, calculated as the ratio of total foreign tax credits to total foreign-source income, was 33.8 percent in 1986. The average foreign tax rate for manufacturing industries (other than petroleum, which has its own foreign tax credit "basket") was 33.6 percent. A weighted average of foreign tax rates that uses foreign-source rents, royalties, and license fees as weights is 33.2 percent, which closely approximates the other two averages. From this rough test it appears that the foreign tax-credit positions of firms in industries that generate substantial foreign-source royalties are unlikely to differ significantly from firms in other industries.
Applying the figures from Table 4 and the estimates from Goodspeed and Frisch (1989) to R&D-performing firms,36 it follows that the Tax Reform Act of 1986 was responsible for lowering the required marginal productivity of R&D performed in the United States for use abroad by $0.26 (the difference between $1.00 and $0.74) for the 28 percent of all firms (the difference between 78 percent and 50 percent) with deficit The aggregate effect of the tax change is equivalent to raising the required marginal productivity of R&D performed in the United States for use abroad by 1 percent. This aggregate figure masks a considerable amount of heterogeneity between firms in the degree to which the 1986 tax change affects their incentives to do R&D in the United States; nevertheless, it should not be surprising that, under these circumstances, the fraction of American-controlled R&D performed in foreign markets did not increase greatly after 1986. R&D performed in the United States for use abroad is the category of R&D expenditure that is most likely to move offshore in response to changing tax incentives. The 1986 tax change did not influence the cost of performing R&D abroad for use abroad, and only mildly (6 percent) increased the required marginal productivity of R&D performed in the United States for use in the United States by firms with excess foreign tax credits. Since the United States continues to tax heavily R&D performed abroad by American-owned affiliates for use in the U.S. market, the 6 percent rise in the effective cost of R&D performed in the United States for use in the United States is unlikely to generate a substantial outflow of R&D to foreign countries. Instead, the tax change is likely to reduce mildly the U.S. R&D expenditures of the 78 percent of all firms that are affected.
Forms of Technology Exports
The attractive tax treatment of foreign-source royalty income received by U.S. firms with excess foreign tax credits is, in part, responsible for the forms in which American firms typically export their technologies to foreign countries. Table 9 compares annual foreign-source royalties received by Americans to total R&D performed outside the United States by American companies during the years 1985-1991. Royalties reported in this table are restricted to categories of foreign-source receipts that are most likely to be related to R&D activities in the United States.37 Table 9 Royalties reported in Table 9 include receipts from all foreign sources "for the use or sale of intangible property rights, including patents, industrial processes, trademarks, copyrights, franchises, designs, know-how, formulas, techniques, and manufacturing rights." This category of technology-related, gross-royalty receipts is reported by the U.S. U.S. operations in individual foreign countries reflect the tax treatment of R&D performed in the United States for use abroad. Table 10 presents a country-level breakdown of the R&D activity of majorityowned U.S. affiliates in foreign countries in 1989. All twenty-two countries in which U.S. affiliates spend $10 million or more on R&D are included in Table 10 ; countries are ranked in order of the R&D intensity (measured as the ratio of R&D expenditures to ownership of property, plant, and equipment) of local U.S. operations. The table reports royalty payments by U.S. affiliates to their parent U.S. firms; as the last column of Table 10 indicates, local R&D expenditures are smaller than these royalty payments in all but five countries.38 the second line of Table 9 with 1986 royalty receipts in the first line of Table 8 indicates the restrictiveness of the technology-related category of royalty receipts: Table 9 reports royalty receipts of $6.9 billion for 1986, whereas Table 8 reports royalties of $11.9 billion.
The five countries are Germany, the United Kingdom, Brazil, Belgium, and Israel. A comparison of the ranks in column 2 and column 8 shows that R&D-intensive foreign operations are also often royalty-intensive, which suggests that U.S. and foreign R&D might be complementary at country levels of aggregation. The existence of this kind of complementarity at the firm level would challenge the traditional view of the effect of higher R&D costs at home on the movement of R&D offshore. Note: Dollar amounts are millions of current dollars. Royalties include receipts from all foreign sources "for the use or sale of intangible property rights, including patents, industrial processes, trademarks, copyrights, franchises, designs, know-how, formulas, techniques, and manufacturing rights." Additional tax revenue is calculated by applying the average fraction of foreign-source income accruing to manufacturing firms with excess foreign tax credits (50 percent in 1985 and 1986; 64 percent in 1987; 78 percent in 1988-1991) to foreign-source royalties, and multiplying by the statutory U.S. corporate tax rate. See Hall (1993) for estimates of the revenue cost of the R&E credit.
Revenue Cost of Foreign-Source Royalty Treatment
One final indicator of the importance of the tax treatment afforded foreign-source royalties is the tax revenue that the U.S. government would collect, excluding any behavioral responses, if royalties received from foreign payors were treated as U.S. -source income. Table 11 presents this calculation. The first column reports Americans' foreignsource, technology-related royalty receipts for 1985-1991. The second column reports the additional tax revenue these royalties would generate if they had U.S. source for tax purposes, assuming that taxpayers receiving the royalties are subject to prevailing U.S. statutory corporate tax rates and that the figures from Goodspeed and Frisch (1989) accurately represent the foreign tax-credit status of royalty recipients.39 The estimates reported in Table 11 indicate that the revenue cost of the U.S. tax system's treatment of foreign-source royalty income changed dramatically between 1985 and 1991: the cost rose from $1.3 billion in 1985 to $4.7 billion in 1991. This change reflects the growing volume of foreignsource royalty receipts over the 1985-1991 period, and the increased frac-
The estimates in column two of Table 11 are obtained by applying the average fraction of foreign-source income accruing to manufacturing firms with excess foreign tax credits (50 percent in 1985 and 1986; 64 percent [the mean of 50 percent and 78 percent] in 1987; 78 percent in 1988-1991) to foreign-source royalties, and multiplying by the statutory U.S. corporate tax rate (46 percent in 1985 and 1986; 40 percent in 1987; 34 percent in 1988-1991 Hall (1993) and presented in column 3 of Table 11 . By 1991, the cost of the R&E credit was $900 million, or less than one fifth the cost of allowing firms to use excess foreign tax credits to reduce their U.S. tax liabilities on foreign-source royalty income. Of course, the intent of the R&E credit is to encourage marginal R&D projects without subsidizing inframarginal R&D, whereas the treatment of foreign-source royalties draws no such distinction, and may treat favorably royalties generated by activities other than R&D.
Nevertheless, the difference between $4.7 billion and $900 million reflects the importance of foreign-source royalty treatment to American firms undertaking R&D in the United States.
CONCLUSION
The responsiveness of R&D activity to its tax treatment carries many implications for the design of tax policy toward R&D, particularly insofar as multinational firms are concerned. American multinationals adjust their R&D spending levels sharply in response to tax changes, but in spite of the frequent changes in U.S. tax law in the 1980s, American firms moved very little of their R&D out of the United States and into foreign centers. Part of the explanation for the continued importance of the United States as a home to R&D lies in the favorable tax treatment of foreign-source royalty income received by U.S. firms with excess foreign tax credits. U.S. tax law encourages firms with excess foreign tax credits to perform R&D in the United States and license the resulting technology abroad. From a national standpoint, this policy has the effect of maintaining R&D at home, where it may generate valuable economic spillovers, and does so for that segment of R&D activity that is otherwise most likely to be performed in foreign locations that are close to users of the technology it produces. Interestingly, U.S. tax law has this effect only on those firms with excess foreign tax credits; firms with deficit foreign tax credits do not receive the same advantageous tax treatment of their foreign-source royalty receipts. It is this distinction that is responsible for the heterogeneous incentives created by the Tax Reform Act of 1986, and the failure of the 1986 Act to change dramatically the fraction of R&D performed abroad by American firms. The U.S. government's practice, in the 1980s and 1990s, of enacting only temporary rules governing the tax treatment of R&D activity re-flects both the effect of self-imposed budgetary rules and a lack of consensus over the appropriate treatment of R&D. Part of the reason that a consensus has not emerged may have to do with the complexity, and relative obscurity, of some of the tax provisions that affect the incentives multinational firms have to do R&D in the United States and abroad. In spite of their obscurity, these provisions have important consequences, as indicated by the far greater revenue impact of the tax treatment of foreign-source royalty income than the revenue cost of the R&E tax credit. It is worth bearing in mind the incentives currently provided by U.S. tax law when evaluating proposed alternative tax treatments of R&D.
